Replies to post #6675 on Vericel Corp. (VCEL)

[lasers]

$VCEL had a -$0.07 EPS Jun 30, 2017 Qtr which is a significant growth in that Qtr vs its previous Qtrs and beat all Analysts Estimates. This significant growth was primarily due to earnings from MACI and Epicel combined with cost reductions of its R&D Clinical Trials, primarily DCM. The Sept 30 Qtr will be reported on approx Nov 10, 2017 in 6 weeks.

https://clinicaltrials.gov/ct2/show/NCT01670981?term=aastrom&rank=9

This study is ongoing, but not recruiting participants.